Legend Biotech Stock Clears Key FDA Hurdle With LB2501 IND Approval

Simply Wall St.10-18

Legend Biotech reported that the FDA cleared its IND application for LB2501, an investigational in vivo CAR-T therapy that aims to generate dual CD19/CD20 targeting cells within patients for relapsed ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2676526929?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","is_english":true,"pubTime":"2026-10-18 10:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2676526929","market":"sg","top_or_hot":-1,"title":"Legend Biotech Stock Clears Key FDA Hurdle With LB2501 IND Approval","media":"Simply Wall St.","content":"<div>\n<p>Legend Biotech reported that the FDA cleared its IND application for LB2501, an investigational in vivo CAR-T therapy that aims to generate dual CD19/CD20 targeting cells within patients for relapsed ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-stock-clears-key-fda-hurdle-with-lb2501-ind-a\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Legend Biotech Stock Clears Key FDA Hurdle With LB2501 IND Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLegend Biotech Stock Clears Key FDA Hurdle With LB2501 IND Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-18 10:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-stock-clears-key-fda-hurdle-with-lb2501-ind-a><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Legend Biotech reported that the FDA cleared its IND application for LB2501, an investigational in vivo CAR-T therapy that aims to generate dual CD19/CD20 targeting cells within patients for relapsed ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-stock-clears-key-fda-hurdle-with-lb2501-ind-a\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CANC","symbol_name":"TEMA ONCOLOGY ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-stock-clears-key-fda-hurdle-with-lb2501-ind-a","article_id":"2676526929","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/legend-biotech-stock-clears-key-fda-hurdle-with-lb2501-ind-a","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2676526929","pubTimestamp":1792291187,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Legend Biotech reported that the FDA cleared its IND application for LB2501, an investigational in vivo CAR-T therapy that aims to generate dual CD19/CD20 targeting cells within patients for relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma.\nThe therapy is designed as an off-the-shelf, single-infusion treatment built on Legend Biotech’s TaVec platform and is being studied without lymphodepleting chemotherapy, which could have important implications for...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CANC":"TEMA ONCOLOGY ETF","BK4505":"高瓴资本持仓","MEMS":"MATTHEWS EMERGING MARKETS DISCOVERY ACTIVE ETF","LEGN":"传奇生物","MEDI":"HARBOR HEALTH CARE ETF","BK4581":"高盛持仓","BK4588":"碎股","BK4585":"ETF&股票定投概念","LABU":"三倍做多标普生物-Direxion","BK4139":"生物科技","XBI":"SPDR S&P Biotech ETF"},"translate_title":"Legend Biotech 股票通过 LB2501 IND 批准扫清了 FDA 的关键障碍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"XBI":1.5,"LEGN":1.5,"CANC":0.6,"MEDI":0.6,"MEMS":0.6},"content_text":"Legend Biotech reported that the FDA cleared its IND application for LB2501, an investigational in vivo CAR-T therapy that aims to generate dual CD19/CD20 targeting cells within patients for relapsed or refractory B-cell malignancies, including B-cell non-Hodgkin lymphoma. The therapy is designed as an off-the-shelf, single-infusion treatment built on Legend Biotech’s TaVec platform and is being studied without lymphodepleting chemotherapy, which could have important implications for treatment logistics, costs, and patient access if future trial data are supportive. The next area of focus is how Legend Biotech’s LB2501 in vivo CAR-T IND clearance could influence the broader investment narrative around its pipeline.  Scan beyond Legend Biotech and compare this LB2501 step-change with a curated list of other late-stage opportunities in oncology and complex therapies through the 20 high quality undiscovered gems. AdvertisementLegend Biotech Investment Narrative Recap To own Legend Biotech, you need to believe CARVYKTI can support the business while a broader cell therapy pipeline matures and begins to diversify revenue. LB2501 fits that story as an early proof point for Legend’s in vivo ambitions, but the IND clearance itself does not change the near term focus on execution in multiple myeloma and global launches. The main near term swing factor remains how efficiently Legend and its partners scale manufacturing and access for CARVYKTI while keeping costs in check. The biggest risk stays the same. Heavy dependence on one commercial product and continued losses of US$91.5 million keep execution and capital discipline front and center. The other recent development that matters here is the US$178.8 million shelf registration for up to 9,550,000 American Depositary Shares. For a research heavy group like Legend Biotech, extra equity capacity can be important when running parallel programs such as CARVYKTI label expansions and the TaVec based LB2501 platform. For you as a shareholder, that filing mostly speaks to funding strategy and dilution risk rather than changing the fundamental thesis. Any future drawdown under the shelf would likely be weighed against the need to support trials like the planned US Phase 1/2 LB2501 study and ongoing manufacturing build out tied to key catalysts in the pipeline. What The Current Legend Biotech Forecasts Assume Legend Biotech's narrative projects US$2.1b revenue and US$399.0 million earnings by 2029. This implies 19.0% yearly revenue growth and a swing in earnings of about US$491 million from a US$91.5 million loss today. Uncover why Legend Biotech's fair value indicates a 153% potential upside to its current price, which could narrow quickly. NasdaqGS:LEGN 1-Year Stock Price Chart Exploring Other Perspectives One alternate angle to explore is how bullish analysts view LB2501 as a potential early signal for pipeline breadth at Legend Biotech. Before this IND clearance, the most optimistic forecasts already pencilled in about US$2.5b revenue and US$723.5 million earnings by 2029. Your own view on that optimism may shift as LB2501 data emerges. Explore 3 other Legend Biotech fair value estimates, including one that suggests as much as 610% upside from the current price! Decide For Yourself Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.  A great starting point for your Legend Biotech research is our analysis highlighting 4 key rewards that could impact your investment decision. See our latest analysis for Legend Biotech. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Legend Biotech's overall financial health at a glance.  Looking For More Ideas Beyond Legend Biotech? Once you have a view on Legend Biotech, it can help to broaden your watchlist with other stocks that match the kind of risk and reward profile you want in your portfolio. The Simply Wall St Screener lets you filter the market quickly so you spend more time assessing quality and less time sifting through noise.  If you want potential mispricing with quality in mind, start with a focused set of 33 high quality undervalued stocks that already combine strong fundamentals with attractive valuations. For a stronger focus on resilience, filter for companies that score well on financial strength and see which ones make it into the list of solid balance sheet and fundamentals (25 results). If capital preservation is a priority, narrow the field to 32 resilient stocks with low risk scores and concentrate your research on businesses with lower risk scores.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2676526929","isCrawlerRequest":true}